z-logo
open-access-imgOpen Access
Revisiting the term neuroprotection in chronic and degenerative diseases
Author(s) -
Marco Orsini,
Osvaldo J. M. Nascimento,
André Matta,
Carlos Henrique Melo Reis,
Olivia Gameiro de Souza,
Víctor Hugo Bastos,
Rayele Moreira,
Pedro Ribeiro,
Stênio Karlos Alvim Fiorelli,
Pietro Novellino,
Bruno Lima Pessôa,
Mariana Faucz Munhoz da Cunha,
Camila Pupe,
Pedro S. Morales,
Pedro Ferreira Moreira Filho,
Eduardo Tavares Lima Trajano,
Acary Bulle Oliveira
Publication year - 2016
Publication title -
neurology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.39
H-Index - 16
ISSN - 2035-8377
DOI - 10.4081/ni.2016.6311
Subject(s) - neuroprotection , medicine , amyotrophic lateral sclerosis , neuroscience , disease , pharmacology , pathology , biology
Thanks to the development of several new researches, the lifetime presented a significant increase, even so, we still have many obstacles to overcome − among them, manage and get responses regarding neurodegenerative diseases. Where we are in the understanding of neuroprotection? Do we really have protective therapies for diseases considered degeneratives such as amyotrophic lateral sclerosis and its variants, Parkinson’s disease, Alzheimer’s disease and many others? Neuroprotection is defined by many researches as interactions and interventions that can slow down or even inhibit the progression of neuronal degeneration process. We make some considerations on this neuroprotective effect

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom